Home/Filings/4/0001209191-22-000967
4//SEC Filing

Haddock David 4

Accession 0001209191-22-000967

CIK 0000019411other

Filed

Jan 3, 7:00 PM ET

Accepted

Jan 4, 5:10 PM ET

Size

13.5 KB

Accession

0001209191-22-000967

Insider Transaction Report

Form 4
Period: 2022-01-04
Haddock David
General Counsel & Secretary
Transactions
  • Disposition to Issuer

    Restricted Stock Units

    2022-01-0411,3090 total
    Exercise: $0.00Common Stock (11,309 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2022-01-048,4730 total
    Exercise: $0.00Common Stock (8,473 underlying)
  • Disposition to Issuer

    Ordinary Common Stock, $0.01 par value

    2022-01-042,9610 total
  • Disposition to Issuer

    Performance-Based Restricted Stock Units

    2022-01-0410,6050 total
    Exercise: $0.00Common Stock (10,605 underlying)
Footnotes (5)
  • [F1]In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").
  • [F2]Not applicable.
  • [F3]These unvested restricted stock units previously granted by the Issuer on March 2, 2020 , which provided for vesting in equal increments on each of March 2, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
  • [F4]These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
  • [F5]These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.

Issuer

MAGELLAN HEALTH INC

CIK 0000019411

Entity typeother

Related Parties

1
  • filerCIK 0001501357

Filing Metadata

Form type
4
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 5:10 PM ET
Size
13.5 KB